High Sensitivity C-reactive Protein: An Emerging Role in Cardiovascular Risk Assessment

References

• Ross R, Glomset J, Harker L. Response to injury and atherogenesis. Am J Pathol 1977; 86: 675–84.
   PubMed Web of Science ®Google Scholar
• Ross R, Glomset JA. The pathogenesis of atherosclerosis (first of two parts). N Engl J Med 1976; 295: 369–77.
   PubMed Web of Science ®Google Scholar
• Cybulsky MI, Gimbrone MA, Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991; 251: 788–91.
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999; 138: S419–S420.
   PubMed Web of Science ®Google Scholar
• Leonard EJ, Yoshimura T. Human monocyte chemoattractant protein-1 (MCP-1). Immunol Today 1990; 11: 97–101.
   PubMedGoogle Scholar
• Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839–43.
   PubMed Web of Science ®Google Scholar
• Hansson GK, Jonasson L, Seifert PS, Stemme S. Immune mechanisms in atherosclerosis. Arteriosclerosis 1989; 9: 567–78.
   PubMedGoogle Scholar
• Khoo JC, Miller E, McLoughlin P, Steinberg D. Enhanced macrophage uptake of low density lipoprotein after self-aggregation. Arteriosclerosis 1988; 8: 348–58.
   PubMedGoogle Scholar
• Aqel NM, Ball RY, Waldmann H, Mitchinson MJ. Monocytic origin of foam cells in human atherosclerotic plaques. Atherosclerosis 1984; 53: 265–71.
   PubMed Web of Science ®Google Scholar
• Stary HC, Chandler AB, Glagov S, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1994; 89: 2462–78.
   Google Scholar
• Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987; 316: 1371–5.
   PubMed Web of Science ®Google Scholar
• Steinberg D. Low-density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997; 272: 20963–6.
   PubMed Web of Science ®Google Scholar
• Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low density lipopro-teins: a potential role in recruitment and retention of monocyte/macrophages during atherogen-esis. Proc Natl Acad Sci USA 1987; 84: 2995–8.
   PubMed Web of Science ®Google Scholar
• Bhakdi S, Dorweiler B, Kirchmann R, et al. On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety. J Exp Med 1995; 182: 1959–71.
   PubMed Web of Science ®Google Scholar
• Klouche M, Gottschling S, Gerl V, et al. Atherogenic properties of enzymatically degraded LDL: selective induction of MCP-1 and cytotoxic effects on human macrophages. Arterioscler Thromb Vasc Biol 1998; 18: 1376–85.
   PubMed Web of Science ®Google Scholar
• Kronenberg F, Steinmetz A, Kostner GM, Dieplinger H. Lipoprotein(a) in health and disease. Crit Rev Clin Lab Sci 1996; 33: 495–543.
   PubMed Web of Science ®Google Scholar
• Gotlieb AL, Langille BL. In: Fuster V, Ross R, Topol EJ, Eds. The role of rheology in atherosclerotic coronary artery disease. Atherosclerosis and coronary artery disease. pp. 595-606. Philadelphia: Lippincott-Raven, 1996.
   Google Scholar
• Walpola PL, Gotlieb AI, Cybulsky MI, Langille BL. Expression of ICAM-1 and VCAM-1 and monocyte adherence in arteries exposed to altered shear stress. Arterioscler.Thromb.Vasc.Biol. 1995; 15: 2–10.
   PubMed Web of Science ®Google Scholar
• Resnick N, Collins T, Atkinson W, Bonthron DT, Dewey CF, Jr., Gimbrone MA, Jr. Platelet-derived growth factor B chain promoter contains a cis-acting fluid shear-stress-responsive element. Proc Natl Acad Sci USA 1993; 90: 4591–5.
   PubMed Web of Science ®Google Scholar
• Hajjar DP, Fabricant CG, Minick CR, Fabricant J. Virus-induced atherosclerosis. Herpesvirus infection alters aortic cholesterol metabolism and accumulation. Am J Pathol 1986; 122: 62–70.
   PubMed Web of Science ®Google Scholar
• Ericson K, Saldeen TG, Lindquist O, Pahlson C, Mehta JL. Relationship of Chlamydia pneumoniae infection to severity of human coronary atherosclerosis. Circulation 2000; 101: 2568–71.
   PubMed Web of Science ®Google Scholar
• Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocar-dial infarction. Circulation 1997; 96: 404–7.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Kundsin RB, Stampfer MJ, Poulin S, Hennekens CH. Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction. Circulation 1999; 99: 1161–4.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Stampfer MJ, Wang F. Prospective study of herpes simplex virus, cytomegalovirus, and the risk of future myocardial infarction and stroke. Circulation 1998; 98: 2796–9.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Buring JE, Kundsin R, Shih J. Baseline IgG antibody titers to Chlamydia pneumoniae, Helicobacter pylori, herpes simplex virus, and cytomegalovirus and the risk for cardiovascular disease in women. Ann Intern Med 1999; 131: 573–7.
   PubMed Web of Science ®Google Scholar
• Kume S, Takeya M, Mori T, et al. Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. Am J Pathol 1995; 147: 654–67.
   PubMed Web of Science ®Google Scholar
• Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 1988; 240: 1546–8.
   PubMed Web of Science ®Google Scholar
• Schmidt AM, Hori O, Chen JX, et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995; 96: 1395–403.
   PubMed Web of Science ®Google Scholar
• Vlassara H, Fuh H, Donnelly T, Cybulsky M. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med 1995; 1: 447–56.
   PubMed Web of Science ®Google Scholar
• Heeschen C, Jang JJ, Weis M, Pathak A, Kaji S, Hu RS et al. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med 2001; 7: 833–9.
   PubMed Web of Science ®Google Scholar
• Powell JT. Vascular damage from smoking: disease mechanisms at the arterial wall. Vasc Med 1998; 3: 21–8.
   PubMedGoogle Scholar
• Folts JD, Gering SA, Laibly SW, Bertha BG, Bonebrake FC, Keller JW. Effects of cigarette smoke and nicotine on platelets and experimental coronary artery thrombosis. Adv Exp Med Biol 1990; 273: 339–58.
   PubMedGoogle Scholar
• Biasucci LM, Colizzi C, Rizzello V, Vitrella G, Crea F, Liuzzo G. Role of inflammation in the pathogenesis of unstable coronary artery diseases. Scand J Clin Lab Invest Suppl 1999; 230: 12–22.
   PubMedGoogle Scholar
• Biasucci LM, Liuzzo G, Angiolillo DJ, Sperti G, Maseri A. Inflammation and acute coronary syndromes. Herz 2000; 25: 108–12.
   PubMed Web of Science ®Google Scholar
• Hansson GK, Jonasson L, Lojsthed B, Stemme S, Kocher O, Gabbiani G. Localization of T lymphocytes and macrophages in fibrous and complicated human atherosclerotic plaques. Atherosclerosis 1988; 72: 135–41.
   PubMed Web of Science ®Google Scholar
• Hansson GK, Holm J, Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol 1989; 135: 169–75.
   PubMed Web of Science ®Google Scholar
• Richardson PD, Davies MJ, Born GV. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989; 2: 941–4.
   PubMed Web of Science ®Google Scholar
• van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994; 89: 36–44.
   PubMed Web of Science ®Google Scholar
• Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 1994; 90: 775–8.
   PubMed Web of Science ®Google Scholar
• Falk E. Why do plaques rupture? Circulation 1992; 86: III30-III42.
   Google Scholar
• Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91: 2844–50.
   PubMed Web of Science ®Google Scholar
• Libby P, Sukhova G, Lee RT, Galis ZS. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol 1995; 25 Suppl 2: S9–12.
   PubMed Web of Science ®Google Scholar
• Sukhova GK, Schonbeck U, Rabkin E, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999; 99: 2503–9.
   PubMed Web of Science ®Google Scholar
• Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Libby P. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann N Y Acad Sci 1995; 748: 501–7.
   PubMed Web of Science ®Google Scholar
• Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493–503.
   PubMed Web of Science ®Google Scholar
• Johnson AM, Sampson EJ, Blirup-Jensen S, Svendsen PJ. Recommendations for the selection and use of protocols for assignment of values to reference materials. Eur J Clin Chem Clin Biochem 1996; 34: 279–85.
   PubMedGoogle Scholar
• Zhang Y, Deng Y, Wendt T, et al. Intravenous somatic gene transfer with antisense tissue factor restores blood flow by reducing tumor necrosis factor-induced tissue factor expression and fibrin deposition in mouse meth-A sarcoma. J Clin Invest 1996; 97: 2213–24.
   PubMed Web of Science ®Google Scholar
• Nemerson Y. Tissue factor and hemostasis. Blood 1988; 71: 1–8.
   PubMed Web of Science ®Google Scholar
• Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications. Circulation 1989; 80: 198–205.
   PubMed Web of Science ®Google Scholar
• Moreno PR, Bernardi VH, Lopez-Cuellar J, et al. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation 1996; 94: 3090–7.
   PubMed Web of Science ®Google Scholar
• Oliveira EB, Gotschlich EC, Liu TY. Primary structure of human C-reactive protein. Proc Natl Acad Sci USA 1977; 74: 3148–51.
   PubMed Web of Science ®Google Scholar
• Tillett WS, Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med 1930; 52: 561–7.
   PubMedGoogle Scholar
• Gotschlich EC, Liu TY, Oliveira E. Binding of C-reactive protein to C-carbohydrate and PC-substituted protein. Ann N Y Acad Sci 1982; 389: 163–71.
   PubMed Web of Science ®Google Scholar
• Whitehead AS, Bruns GA, Markham AF, Colten HR, Woods DE. Isolation of human C-reactive protein complementary DNA and localization of the gene to chromosome 1. Science 1983; 221: 69–71.
   PubMed Web of Science ®Google Scholar
• Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in “active” coronary artery disease. Am J Cardiol 1990; 65: 168–72.
   PubMed Web of Science ®Google Scholar
• Pepys MB. C-reactive protein 50 years on. Lancet 1981; 1: 653–7.
   PubMed Web of Science ®Google Scholar
• De Beer FC, Hind CR, Fox KM, Allan RM, Maseri A, Pepys MB. Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J 1982; 47: 239–43.
   PubMedGoogle Scholar
• Pietila K, Harmoinen A, Poyhonen L, Ruosteenoja R. C-reactive protein in subendocardial and transmural myocardial infarcts. Clin Chem 1986; 32: 1596–7.
   PubMed Web of Science ®Google Scholar
• Pietila K, Hermens WT, Harmoinen A, et al. Comparison of peak serum C-reactive protein and hydroxybutyrate dehydrogenase levels in patients with acute myocardial infarction treated with alteplase and streptokinase. Am J Cardiol 1997; 80: 1075–7.
   PubMed Web of Science ®Google Scholar
• Pietila K, Harmoinen A, Poyhonen L, Koskinen M, Heikkila J, Ruosteenoja R. Intravenous streptokinase treatment and serum C-reactive protein in patients with acute myocardial infarction. Br Heart J 1987; 58: 225–9.
   PubMedGoogle Scholar
• Pietila KO, Harmoinen AP, Jokiniitty J, Pasternack AI. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart J 1996; 17: 1345–9.
   PubMed Web of Science ®Google Scholar
• Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 1997; 43: 52–8.
   PubMed Web of Science ®Google Scholar
• Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994; 331: 417–24.
   PubMed Web of Science ®Google Scholar
• Liuzzo G, Biasucci LM, Rebuzzi AG, et al. Plasma protein acute-phase response in unstable angina is not induced by ischemic injury. Circulation 1996; 94: 2373–80.
   PubMed Web of Science ®Google Scholar
• Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1998; 31: 1460–5.
   PubMed Web of Science ®Google Scholar
• Rebuzzi AG, Quaranta G, Liuzzo G, et al. Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris. Am J Cardiol 1998; 82: 715–9.
   PubMed Web of Science ®Google Scholar
• de Winter RJ, Bholasingh R, Lijmer JG, et al. Independent prognostic value of C-reactive protein and troponin I in patients with unstable angina or non-Q-wave myocardial infarction. Cardiovasc Res 1999; 42: 240–5.
   PubMed Web of Science ®Google Scholar
• Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 antiPlatelet therapy in unstable angina refractory to standard treatment trial. J Am Coll Cardiol 2000; 35: 1535–42.
   PubMed Web of Science ®Google Scholar
• Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease. N Engl J Med 2000; 343: 1139–47.
   PubMed Web of Science ®Google Scholar
• Ferreiros ER, Boissonnet CP, Pizarro R, et al. Independent prognostic value of elevated C-reactive protein in unstable angina. Circulation 1999; 100: 1958–63.
   PubMed Web of Science ®Google Scholar
• Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999; 99: 855–60.
   PubMed Web of Science ®Google Scholar
• ECAT angina pectoris study: baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993; 14: 8–17.
   PubMed Web of Science ®Google Scholar
• Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997; 349: 462–6.
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001–9.
   PubMed Web of Science ®Google Scholar
• Lewis SJ, Sacks FM, Mitchell JS, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol 1998; 32: 140–6.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98: 839–44.
   PubMed Web of Science ®Google Scholar
• Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996; 144: 537–47.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973–9.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97: 2007–11.
   PubMed Web of Science ®Google Scholar
• Koenig W, Sund M, Frohlich M, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237–42.
   PubMed Web of Science ®Google Scholar
• Roivainen M, Viik-Kajander M, Palosuo T, et al. Infections, inflammation, and the risk of coronary heart disease. Circulation 2000; 101: 252–7.
   PubMed Web of Science ®Google Scholar
• Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999; 106: 506–12.
   PubMed Web of Science ®Google Scholar
• Tracy RP, Lemaitre RN, Psaty BM, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997; 17: 1121–7.
   PubMed Web of Science ®Google Scholar
• Mendall MA, Strachan DP, Butland BK, et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J 2000; 21: 1584–90.
   PubMed Web of Science ®Google Scholar
• Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000; 321: 199–204.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836–43.
   PubMed Web of Science ®Google Scholar
• Gottsauner-Wolf M, Zasmeta G, Hornykewycz S, et al. Plasma levels of C-reactive protein after coronary stent implantation. Eur Heart J 2000; 21: 1152–8.
   PubMed Web of Science ®Google Scholar
• Buffon A, Liuzzo G, Biasucci LM, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999; 34: 1512–21.
   PubMed Web of Science ®Google Scholar
• Tomoda H, Aoki N. Prognostic value of C-reactive protein levels within six hours after the onset of acute myocardial infarction. Am Heart J 2000; 140: 324–8.
   PubMed Web of Science ®Google Scholar
• Milazzo D, Biasucci LM, Luciani N, et al. Elevated levels of C-reactive protein before coronary artery bypass grafting predict recurrence of ischemic events. Am J Cardiol 1999; 84: 459-61, A9.
   Google Scholar
• Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998; 97: 425–8.
   PubMed Web of Science ®Google Scholar
• van den Berg RH, Faber-Krol MC, Sim RB, Daha MR. The first subcomponent of complement, C1q, triggers the production of IL-8, IL-6, and monocyte chemoattractant peptide-1 by human umbilical vein endothelial cells. J Immunol 1998; 161: 6924–30.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285: 2481–5.
   PubMed Web of Science ®Google Scholar
• Di Napoli M, Papa F, Bocola V. C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke 2001; 32: 917–24.
   PubMed Web of Science ®Google Scholar
• Benzaquen LR, Nicholson-Weller A, Halperin JA. Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med 1994; 179: 985–92.
   PubMed Web of Science ®Google Scholar
• Torzewski M, Torzewski J, Bowyer DE, et al. Immunohistochemical colocalization of the terminal complex of human complement and smooth muscle cell alpha-actin in early atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1997; 17: 2448–52.
   PubMed Web of Science ®Google Scholar
• Schmiedt W, Kinscherf R, Deigner HP, et al. Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 1998; 18: 1790–5.
   PubMed Web of Science ®Google Scholar
• Bhakdi S, Torzewski M, Klouche M, Hemmes M. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol 1999; 19: 2348–54.
   PubMed Web of Science ®Google Scholar
• Torzewski J, Torzewski M, Bowyer DE, et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 1998; 18: 1386–92.
   PubMed Web of Science ®Google Scholar
• Pasceri V, Chang J, Willerson JT, Yeh ET. Modulation of c-reactive protein-mediated mono-cyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001; 103: 2531–4.
   PubMed Web of Science ®Google Scholar
• Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165–8.
   PubMed Web of Science ®Google Scholar
• Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001; 103: 1194–7.
   PubMed Web of Science ®Google Scholar
• Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82: 513–20.
   PubMed Web of Science ®Google Scholar
• Hatanaka K, Li XA, Masuda K, Yutani C, Yamamoto A. Immunohistochemical localization of C-reactive protein-binding sites in human atherosclerotic aortic lesions by a modified streptavidin-biotin-staining method. Pathol Int 1995; 45: 635–41.
   PubMed Web of Science ®Google Scholar
• Lagrand WK, Niessen HW, Wolbink GJ, et al. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 1997; 95: 97–103.
   PubMed Web of Science ®Google Scholar
• Hoffmeister A, Rothenbacher D, Bazner U, et al. Role of novel markers of inflammation in patients with stable coronary heart disease. Am J Cardiol 2001; 87: 262–6.
   PubMed Web of Science ®Google Scholar
• Morrow DA, Rifai N, Antman EM, et al. Serum amyloid A predicts early mortality in acute coronary syndromes: A TIMI 11A substudy. J Am Coll Cardiol 2000; 35: 358–62.
   PubMed Web of Science ®Google Scholar
• Sacks FM, Ridker PM. Lipid lowering and beyond: results from the CARE study on lipopro-teins and inflammation. Cholesterol and Recurrent Events. Herz 1999; 24: 51–6.
   PubMedGoogle Scholar
• Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000; 148: 209–14.
   PubMed Web of Science ®Google Scholar
• van Aken BE, Jansen J, van Deventer SJ, Reitsma PH. Elevated levels of homocysteine increase IL-6 production in monocytic Mono Mac 6 cells. Blood Coagul Fibrinolysis 2000; 11: 159–64.
   PubMed Web of Science ®Google Scholar
• Biasucci LM, Vitelli A, Liuzzo G, et al. Elevated levels of interleukin-6 in unstable angina. Circulation 1996; 94: 874–7.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767–72.
   PubMed Web of Science ®Google Scholar
• Ikata J, Wakatsuki T, Oishi Y, Oki T, Ito S. Leukocyte counts and concentrations of soluble adhesion molecules as predictors of coronary atherosclerosis. Coron Artery Dis 2000; 11: 445–9.
   PubMed Web of Science ®Google Scholar
• Morisaki N, Saito I, Tamura K, et al. New indices of ischemic heart disease and aging: studies on the serum levels of soluble intercellular adhesion molecule-1 (ICAM-1) and soluble vascular cell adhesion molecule-1 (VCAM-1) in patients with hypercholesterolemia and ischemic heart disease. Atherosclerosis 1997; 131: 43–8.
   PubMed Web of Science ®Google Scholar
• Porsch-Oezcueruemez M, Kunz D, Kloer HU, Luley C. Evaluation of serum levels of solu-bilized adhesion molecules and cytokine receptors in coronary heart disease. J Am Coll Cardiol 1999; 34: 1995–2001.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998; 351: 88–92.
   PubMed Web of Science ®Google Scholar
• de Lemos JA, Hennekens CH, Ridker PM. Plasma concentration of soluble vascular cell adhesion molecule-1 and subsequent cardiovascular risk. J Am Coll Cardiol 2000; 36: 423–6.
   PubMed Web of Science ®Google Scholar
• Cybulsky MI, Iiyama K, Li H, et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001; 107: 1255–62.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001; 103: 491–5.
   PubMed Web of Science ®Google Scholar
• Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993; 118: 956–63.
   PubMed Web of Science ®Google Scholar
• Cook NS, Ubben D. Fibrinogen as a major risk factor in cardiovascular disease. Trends Pharmacol Sci 1990; 11: 444–51.
   PubMed Web of Science ®Google Scholar
• Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332: 635–41.
   PubMed Web of Science ®Google Scholar
• Ma J, Hennekens CH, Ridker PM, Stampfer MJ. A prospective study of fibrinogen and risk of myocardial infarction in the Physicians’ Health Study. J Am Coll Cardiol 1999; 33: 1347–52.
   PubMed Web of Science ®Google Scholar
• Lowe G, Rumley A, Norrie J, et al. Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study. Thromb Haemost 2000; 84: 553–8.
   PubMed Web of Science ®Google Scholar
• Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb 1994; 14: 54–9.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101: 2149–53.
   PubMed Web of Science ®Google Scholar
• Cannon CP, McCabe CH, Wilcox RG, Bentley JH, Braunwald E. Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 Investigators. Am J Cardiol 2001; 87: 636-9, A10.
   Google Scholar
• Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998; 279: 1477–82.
   PubMed Web of Science ®Google Scholar
• Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996; 348: 1079–82.
   PubMed Web of Science ®Google Scholar
• Rossen RD. HMG-CoA reductase inhibitors: a new class of anti-inflammatory drugs? J Am Coll Cardiol 1997; 30: 1218–9.
   PubMed Web of Science ®Google Scholar
• Aikawa M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001; 103: 276–83.
   PubMed Web of Science ®Google Scholar
• Williams JK, Sukhova GK, Herrington DM, Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998; 31: 684–91.
   PubMed Web of Science ®Google Scholar
• Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001; 21: 115–21.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100: 230–5.
   PubMed Web of Science ®Google Scholar
• Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103: 1933–5.
   PubMed Web of Science ®Google Scholar
• Siegel D, Swislocki AL. Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1999; 281: 417–9.
   PubMedGoogle Scholar
• Ridker PM, Rifai N, Miles JS, Downs JR, Clearfield M. Lovastatin 20-40mg/day lowers high sensitivity C-reactive protein in AFCAPS/TexCAPs (abstract). Circulation 2000; Vol 102, suppl. II.
   Google Scholar
• Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959–65.
   PubMed Web of Science ®Google Scholar
• Albert MA, Danielson E, Rifai N. Effect of statin therapy on C-reactive protein levels: The Pravastatin Inflammation/CRP Evaluation (PRINCE). a randomized trial and cohort study. JAMA 2001; 141: 893–9.
   Google Scholar
• Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in c-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001; 103: 1191–3.
   PubMed Web of Science ®Google Scholar
• Devaraj S, Jialal I. Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and type 2 diabetic patients. Free Radic Biol Med 2000; 29: 790–2.
   PubMed Web of Science ®Google Scholar
• Rifai N, Ridker PM. Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. Clin Chem 2001; 47: 28–30.
   PubMed Web of Science ®Google Scholar
• Meier-Ewert HK, Ridker PM, Rifai N, Price N, Dinges DF, Mullington JM. Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem 2001; 47: 426–30.
   PubMed Web of Science ®Google Scholar
• Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, Stanek E. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 2001; 47: 444–50.
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605–13.
   PubMed Web of Science ®Google Scholar
• Cushman M, Meilahn EN, Psaty BM, Kuller LH, Dobs AS, Tracy RP. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol 1999; 19: 893–9.
   PubMed Web of Science ®Google Scholar
• van Baal WM, Kenemans P, van der Mooren MJ, Kessel H, Emeis JJ, Stehouwer CD. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women. Thromb Haemost 1999; 81: 925–8.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999; 100: 713–6.
   PubMed Web of Science ®Google Scholar
• Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999; 100: 717–22.
   PubMed Web of Science ®Google Scholar
• van Baal WM, Kenemans P, van der Mooren MJ, Kessel H, Emeis JJ, Stehouwer CD. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women. Thromb Haemost 1999; 81: 925–8.
   PubMed Web of Science ®Google Scholar
• Wilkins J, Gallimore JR, Moore EG, Pepys MB. Rapid automated high sensitivity enzyme immunoassay of C-reactive protein. Clin Chem 1998; 44: 1358–61.
   PubMed Web of Science ®Google Scholar
• Ledue TB, Weiner DL, Sipe JD, Poulin SE, Collins MF, Rifai N. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem 1998; 35(Pt 6)</b>: 745–53.
   Web of Science ®Google Scholar
• Kapyaho K, Welin MG, Tanner P, Karkkainen T, Weber T. Rapid determination of C-reactive protein by enzyme immunoassay using two monoclonal antibodies. Scand J Clin Lab Invest 1989; 49: 389–93.
   PubMed Web of Science ®Google Scholar
• Eda S, Kaufmann J, Molwitz M, Vorberg E. A new method of measuring C-reactive protein, with a low limit of detection, suitable for risk assessment of coronary heart disease. Scand J Clin Lab Invest Suppl 1999; 230: 32–5.
   PubMedGoogle Scholar
• Borque L, Bellod L, Rus A, Seco ML, Galisteo-Gonzalez F. Development and validation of an automated and ultrasensitive immunoturbidimetric assay for C-reactive protein. Clin Chem 2000; 46: 1839–42.
   PubMed Web of Science ®Google Scholar
• Roberts WL, Sedrick R, Moulton L, Spencer A, Rifai N. Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clin Chem 2000; 46: 461–8.
   PubMed Web of Science ®Google Scholar
• Roberts WL, Moulton L, Law TC, et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clin Chem 2001; 47: 418–25.
   PubMed Web of Science ®Google Scholar